Rituximab: a novel treatment for refractory Riedel’s thyroiditis

Autor: Leanne Hunt, Barney Harrison, Matthew Bull, Tim Stephenson, Amit Allahabadia

Publikováno v: Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-6 (2018)

This case report reviews the rare condition of Riedel’s thyroiditis via a patient case. The report highlights the difficulties that one may encounter when managing such a case in regards to patient symptoms, side effects of medications and the rela

Externí odkaz: https://doaj.org/article/0e7d7d774e7a496a8e633aa1009fdbf8

The adult patient with hyponatraemia

Autor: Hirst, C, Allahabadia, A, Cosgrove, J

Publikováno v: In BJA Education October 2015 15(5):248-252

Thyrotoxicosis

Autor: Peter Novodvorsky, Amit Allahabadia

Publikováno v: Medicine. 49:515-521

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::822dd94a9fb778fe3bb8c7017d16b1ed
https://doi.org/10.1016/j.mpmed.2021.05.014

Diagnosis and treatment of primary hypothyroidism

Autor: Allahabadia, Amit, Razvi, Salman, Abraham, Prakash, Franklyn, Jayne

Publikováno v: BMJ: British Medical Journal, 2009 May 01. 338(7703), 1090-1091.

Externí odkaz: https://www.jstor.org/stable/25671490

Adjuvant Rituximab - exploratory trial in young people with Graves’ disease

Autor: Sophie Hambleton, Caroline A Steele, Zainaba Mohamed, John N. S. Matthews, Tim Cheetham, Tim Barratt, Simon H. S. Pearce, Jonathan Prichard, Gillian Watson, Amanda J. Drake, Justin H Davies, Michael Cole, Mario Abinun, Robert D Murray, Nicola Zammitt, Amit Allahabadia, Paul Dimitri, Sonya Carnell

Publikováno v: Cheetham, T, Cole, M, Abinun, M, Allahabadia, A, Barratt, T, Davies, J H, Dimitri, P, Drake, A, Mohamed, Z, Murray, R D, Steele, C, Zammitt, N, Carnell, S, Prichard, J, Watson, G, Hambleton, S, Matthews, J N S & Pearce, S H S 2021, ' Adjuvant Rituximab – exploratory trial in young people with Graves’ disease ', Journal of Clinical Endocrinology & Metabolism . https://doi.org/10.1210/clinem/dgab763

Context Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). Objective We explored whether rituximab (RTX), a B-lymphocyte–depleting agent, would increase remission rates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ed60c648d777841aed9cf4b20677f5
https://doi.org/10.1530/endoabs.77.oc6.1